Farrerol inhibits IL-6 and IL-8 production in LPS-stimulated human gingival fibroblasts by suppressing PI3K/AKT/NF-κB signaling pathway

Farrerol inhibits IL-6 and IL-8 production in LPS-stimulated human gingival fibroblasts by suppressing PI3K/AKT/NF-κB signaling pathway
复制标题

DOI:
10.1016/j.archoralbio.2015.11.007
复制
发表时间:
2016-02-01
影响因子:
3
通讯作者:
Yu, Jin-Long
Yu, Jin-Long
中科院分区:
医学4区
文献类型:
--
作者:
Wang, Qian;Zhang, Bin;Yu, Jin-Long

文献摘要

被引文献

相似文献

目的:杜鹃素是从杜鹃花属植物中分离得到的一种新型2,3-二氢黄酮类化合物,具有抗菌和抗炎作用。本研究采用脂多糖(lipopolysaccharide,LPS)刺激人牙龈成纤维细胞(human gingival fibroblasts,HGFs),观察杜鹃素对HGFs分泌IL-6和IL-8的影响。使用ELISA和qRT-PCR测量IL-6和IL-8的产生。采用Western blotting分析法检测杜鹃醇对LPS诱导的PI 3 K、Akt磷酸化和NF-κ B活化的影响。结果:杜鹃醇以剂量依赖方式抑制LPS诱导的IL-6和IL-8产生。LPS诱导的NF-κ B活化被杜鹃素抑制。结论:杜鹃素通过抑制NF-κ B B的上游分子PI 3 K和Akt的磷酸化,抑制IL-6和IL-8的产生,从而抑制NF-κ B B的活化。Farrerol可以是用于治疗牙周病的治疗剂。(C)2015爱思唯尔有限公司版权所有。
Objectives: Farrerol, a new type of 2,3-dihydro-flavonoid isolated from rhododendron, has been shown to have anti-bacterial and anti-inflammatory activities. In the present study, we investigated the anti-inflammatory effects of farrerol on the production of IL-6 and IL-8 in human gingival fibroblasts (HGFs) treated with lipopolysaccharide (LPS).Methods: The cytotoxicity of farrerol was determined using the MTT assay. The production of IL-6 and IL-8 was measured using ELISA and qRT-PCR. The effects of farrerol on PI3K, Akt phosphorylation, and NF-kappa B activation were detected using western blotting analyses.Results: These results showed that farrerol inhibited LPS-induced IL-6 and IL-8 production in a dose dependent manner. LPS-induced NF-kappa B activation was suppressed by farrerol. Furthermore, farrerol suppressed LPS-induced PI3K and Akt phosphorylation, which are upstream molecules of NF-kappa B.Conclusion: These results indicated that farrerol attenuated IL-6 and IL-8 production by inhibition of PI3K and AKT phosphorylation, resulting in an inhibition of NF-kappa B activation. Farrerol may be a therapeutic agent for the treatment of periodontal disease. (C) 2015 Elsevier Ltd. All rights reserved.